Hepatitis C virus – Associated marginal zone lymphoma. Issue 1 (March 2017)

• Record Type: Journal Article
• Authors: Armand, Marine; Besson, Caroline; Hermine, Olivier; Davi, Frédéric
• Is Part Of: Baillière's best practice and research in clinical haematology. Volume 30:Issue 1/2(2017)
• Page Start: 41
• Page End: 49
• Publication Date: 2017-03
• Subjects: Hepatitis C virus -- Marginal zone lymphoma -- Lymphomagenesis -- Treatment; Hematology -- Periodicals; Blood -- Periodicals; Hematologic Diseases -- Periodicals; Electronic journals; 616
• DOI: 10.1016/j.beha.2017.02.001
• Languages: English
• ISSNs: 1521-6926

Abstract

Abstract: The link between hepatitis C virus (HCV) infection and the development of B-cell non-Hodgkin lymphoma is now well established and based on a number of epidemiological studies. It is further supported by the observation of lymphoma regression after HCV eradication by antiviral treatment. The far most frequent entities are marginal zone lymphoma (MZL) and diffuse large B-cell lymphoma (DLBCL). MZL usually emerge on a background of mixed cryoglobulinemia, a low-grade lymphoproliferation, and often transform into DLBCL, thereby following a multistep oncogenesis process. The role of HCV in lymphomagenesis is not yet fully understood but several mechanisms have been proposed including (i) chronic external stimulation through the B-cell receptor and other surface receptors, and (ii) direct transformation by intracellular viral proteins, the former being probably predominant in MZL. Regression of HCV-associated MZL can be achieved with antiviral therapy and the novel generation of direct-acting antiviral agents appears highly effective and safe for the treatment of these lymphoma.